
Sagimet Biosciences Inc
NASDAQ:SGMT

Fundamental Analysis


Revenue & Expenses Breakdown
Sagimet Biosciences Inc
Balance Sheet Decomposition
Sagimet Biosciences Inc
Current Assets | 152.8m |
Cash & Short-Term Investments | 151.3m |
Other Current Assets | 1.5m |
Non-Current Assets | 7.5m |
Long-Term Investments | 7.4m |
PP&E | 77k |
Free Cash Flow Analysis
Sagimet Biosciences Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Sagimet Biosciences Inc
Revenue
|
0
USD
|
Operating Expenses
|
-54.5m
USD
|
Operating Income
|
-54.5m
USD
|
Other Expenses
|
8.9m
USD
|
Net Income
|
-45.6m
USD
|
SGMT Profitability Score
Profitability Due Diligence
Sagimet Biosciences Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

Score
Sagimet Biosciences Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
SGMT Solvency Score
Solvency Due Diligence
Sagimet Biosciences Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Score
Sagimet Biosciences Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SGMT Price Targets Summary
Sagimet Biosciences Inc
According to Wall Street analysts, the average 1-year price target for
SGMT
is 31.79 USD
with a low forecast of 11.11 USD and a high forecast of 70.35 USD.
Dividends
Current shareholder yield for SGMT is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?